A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers
Received 25 November 2016
Accepted for publication 26 January 2017
Published 24 April 2017 Volume 2017:11 Pages 1301—1313
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Salvatore Bongarzone
Peer reviewer comments 2
Editor who approved publication: Dr Georgios Panos
Jieon Lee,1 Bo-Hyung Kim,2 Kyung-Sang Yu,1 Hee Sun Kim,3 Ji Duck Kim,4 Joo-Youn Cho,1 SeungHwan Lee,1 Namyi Gu5
1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, 2Department of Clinical Pharmacology and Therapeutics, Kyung Hee University College of Medicine and Hospital, Seoul, 3Life Science Research Institute, Daewoong Pharmaceutical Co. Ltd., Yongin, 4Clinical Development Team, Daewoong Pharmaceutical Co. Ltd., Seoul, 5Department of Clinical Pharmacology and Therapeutics, Dongguk University College of Medicine and Ilsan Hospital, Goyang, Republic of Korea
Objectives: DWP05195 is a transient receptor potential vanilloid 1 (TRPV1) antagonist developed for managing pain. The purpose of this study was to evaluate the pharmacodynamics pharmacokinetics, safety, and tolerability of DWP05195 in healthy subjects. This was a first-in-human randomized, double-blinded, placebo-controlled, dose escalation study.
Subjects and methods: DWP05195 or placebo was administered as a single dose of 10–600 mg in the single-dose study and as 100–400 mg once daily for 8 days in the multiple-dose studies. Each study group consisted of 10 subjects (study drug-to-placebo ratio was 8:2). For pharmacodynamics assessment, the heat pain threshold (HPtr), heat pain tolerance (HPtol), perfusion intensity, and flare area ratio of cutaneous blood flow were measured. Safety and tolerability were evaluated throughout the study.
Results: The maximum plasma concentrations and area under the plasma concentration–time curve from zero to the last measurable time dose-dependently increased. HPtr and HPtol tended to increase more after DWP05195 administration than after placebo administration. HPtr and HPtol tended to dose-dependently increase after administration of DWP05195. Cutaneous blood flow was reduced as the dose of DWP05195 increased during the multiple-dose study. DWP05195 was well tolerated up to 600 and 400 mg single- and multiple-dose administrations, respectively.
Conclusion: The pharmacological activity of DWP05195, measured using HPtr and HPtol, increased as expected in a dose-dependent manner owing to increased systemic exposure, indicating that DWP05195 can be used as a TRPV1 antagonist for pain management.
Keywords: DWP05195, TRPV1 antagonist, pain tolerance, pain threshold, capsaicin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS
Published Date: 8 October 2014